# The Use of Trifluoperazine in Transfusion Dependent DBA

> **NCT03966053** · PHASE1,PHASE2 · TERMINATED · sponsor: **Adrianna Vlachos, MD** · enrollment: 2 (actual)

## Conditions studied

- Diamond Blackfan Anemia
- Pure Red Cell Aplasia

## Interventions

- **DRUG:** Trifluoperazine

## Key facts

- **NCT ID:** NCT03966053
- **Lead sponsor:** Adrianna Vlachos, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-13
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-10-13
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Supporter terminated study due to slow subject accrual secondary to COVID pandemic limiting travel to research site.
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03966053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03966053, "The Use of Trifluoperazine in Transfusion Dependent DBA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03966053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*